Show simple item record

dc.creatorBremner, William J.
dc.creatorAmory, John K.
dc.creatorHerbst, Karen L.
dc.creatorAnawalt, Bradley D.
dc.date2008-10-17T20:42:04Z
dc.date2008-10-17T20:42:04Z
dc.date2002-07
dc.date.accessioned2012-06-12T05:52:43Z
dc.date.available2012-06-12T05:52:43Z
dc.date.issued2012-06-12
dc.identifierJ Clin Endocrinol Metab. 2002 Jul;87(7):3215-20
dc.identifierhttp://hdl.handle.net/1773/4394
dc.identifier.urihttps://repositorio.leon.uia.mx/xmlui/1773/4394
dc.descriptionAcyline is a novel GnRH antagonist found in animal studies to be a potent suppressor of circulating gonadotropin and testosterone (T) levels. We conducted the first study of acyline administration to humans. Eight healthy, eugonadal young men were administered a series of acyline injections (0, 2.5, 7.5, 25, and 75 microg/kg), each injection separated by at least 10 d. Serum FSH, LH, and T levels were measured for 7 d after injections. Acyline suppressed FSH, LH, and T levels in a dose-dependent fashion. Maximal suppression occurred after injection of 75 microg/kg acyline, which suppressed FSH to 46.9 +/- 2.5%, LH to 12.4 +/- 2.2%, and T to 13.4 +/- 1.4% of baseline levels, maintaining suppression for over 48 h. Serum acyline levels peaked at 1 h at 18.9 +/- 0.9 ng/ml, remained significantly elevated above background 7 d after injection, and returned to background levels by 14-17 d after injection. Side-effects at the site of injection were limited to infrequent blush and pruritus that resolved within 90 min of injection. Higher doses of acyline might be effective as depot injections for long-lasting gonadotropin suppression in hormone-dependent diseases and for use in male hormonal contraception regimens.
dc.languageen_US
dc.publisherEndocrine Society
dc.subjectmale contraception
dc.subjectandrology
dc.subject5-alpha reductase inhibitors
dc.subjecttestosterone
dc.subjectgonadotropins
dc.subjectSafety
dc.subjectResearch Support, U.S. Gov't, P.H.S.
dc.subjectTestosterone, blood
dc.subjectSkin, drug effects
dc.subjectHumans
dc.subjectAdult
dc.subjectOligopeptides, adverse effects, blood, pharmacology
dc.subjectPruritus, chemically induced
dc.subjectMale
dc.subjectGonadorelin, antagonists & inhibitors
dc.subjectGonadotropins, blood
dc.titleAcyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist
dc.typeArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record